Income Statement
LANTERN PHARMA INC.
LTRN
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | - |
|
Operating Expenses
|
17.98 | 22.22 | 17.88 | 14.43 | 12.59 | 5.91 |
|
Research & Development
|
11.51 | 16.13 | 11.89 | 8.60 | 7.57 | - |
|
Selling, General & Administrative
|
6.46 | 6.09 | 5.98 | 5.83 | 5.02 | 3.66 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-17.98 | -22.22 | -17.88 | -14.43 | -12.59 | -5.91 |
|
Non-Operating Income
|
- | - | - | - | - | - |
|
Interest Income
|
0.44 | 0.74 | 0.77 | 0.20 | 0.07 | - |
|
Interest Expense
|
- | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
0.42 | 0.69 | 1.15 | -0.03 | 0.16 | - |
|
Income Before Tax
|
- | - | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | 12.36 | - |
|
Net Income
|
-17.12 | -20.78 | -15.96 | -14.26 | -12.36 | 5.91 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-17.96 | -22.20 | -17.86 | -14.42 | -12.58 | -5.90 |
|
Earnings Per Share (Basic)
|
-1.57 | -1.93 | -1.47 | -1.31 | - | - |
|
Diluted EPS
|
-1.57 | -1.93 | -1.47 | - | - | - |
|
Weighted Average Shares
|
10.90 | 10.76 | 10.84 | 10.85 | - | - |
|
Diluted Weighted Avg Shares
|
10.90 | 10.76 | 10.84 | - | - | - |
|
Comprehensive Income
|
-17.25 | -20.52 | -15.70 | -14.54 | - | - |